The Magazine for Sleep Professionals
Monday, May 4, 2026
Eisai Co., Ltd. announced a total of seven poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (DAYVIGO® CIV) will be given at the 36th annual meeting of the Associated Professional Sleep Societies (SLEEP 2022), to be held from June 4 to June 8, 2022, in Charlotte, NC. […]
Approval Based on Robust Clinical Development Program That Included Two Pivotal Trials of Nearly 2,000 Patients Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced the U.S. Food and Drug Administration (FDA) approved DAYVIGOTM (lemborexant) 5 mg and 10 mg for the treatment of adult patients with insomnia, characterized […]
Eisai Co., Ltd. and Purdue Pharma L.P. recently announced the publication of a Phase 1 safety study evaluating the impact of bedtime administration with lemborexant on driving performance the following morning. The study, which met its primary endpoint, showed no statistically significant next-day impairment of driving performance in healthy adult and […]
Eisai Co., Ltd. and Purdue Pharma L.P. yesterday announced that two key Phase 1 clinical studies (Study 108 and Study 106) of their investigational sleep/wake regulation agent lemborexant, including a comparison versus zolpidem tartrate extended release (zolpidem ER) and placebo on postural stability and other variables after middle-of-the-night awakening and […]
